Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (STU:2TZ) — Market Cap & Net Worth
Market Cap & Net Worth: Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ)
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (STU:2TZ) has a market capitalization of $692.11 Million (€592.00 Million) as of August 12, 2026. Listed on the STU stock exchange, this Germany-based company holds position #10662 globally and #1244 in its home market, demonstrating a 5.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's stock price €2.96 by its total outstanding shares 200000000 (200.00 Million). See Tianjin Zhong Xin Pharmaceutical Group C net asset quality index to understand what proportion of total assets are financed by equity.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Market Cap History: 2015 to 2026
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's market capitalization history from 2015 to 2026. Data shows growth from $106.74 Million to $692.11 Million (19.49% CAGR). Also see Tianjin Zhong Xin Pharmaceutical Group C assets under control for a full breakdown of the balance sheet.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 2TZ share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.14x
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's market cap is 0.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.32x
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's market cap is 0.32 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $96.10 Million | $6.18 Billion | $422.42 Million | 0.02x | 0.23x |
| 2017 | $93.11 Million | $5.69 Billion | $476.08 Million | 0.02x | 0.20x |
| 2018 | $94.07 Million | $6.36 Billion | $561.68 Million | 0.01x | 0.17x |
| 2019 | $100.73 Million | $6.99 Billion | $625.57 Million | 0.01x | 0.16x |
| 2020 | $104.24 Million | $6.60 Billion | $661.70 Million | 0.02x | 0.16x |
| 2021 | $162.23 Million | $6.91 Billion | $769.14 Million | 0.02x | 0.21x |
| 2022 | $191.45 Million | $8.25 Billion | $861.79 Million | 0.02x | 0.22x |
| 2023 | $378.67 Million | $8.22 Billion | $986.71 Million | 0.05x | 0.38x |
| 2024 | $468.23 Million | $7.31 Billion | $2.23 Billion | 0.06x | 0.21x |
| 2025 | $676.21 Million | $4.92 Billion | $2.13 Billion | 0.14x | 0.32x |
Competitor Companies of 2TZ by Market Capitalization
Companies near Tianjin Zhong Xin Pharmaceutical Group Corporation Limited in the global market cap rankings as of August 12, 2026. Also see cash efficiency ratio of Tianjin Zhong Xin Pharmaceutical Group C for how efficiently the company converts equity into cash flow.
Key companies related to Tianjin Zhong Xin Pharmaceutical Group Corporation Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #532 globally with a market cap of $50.57 Billion USD ( CN¥345.61 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #556 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #532 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.57 Billion | CN¥54.18 |
| #556 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.32 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.10 |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's market cap moved from $106.74 Million to $ 692.11 Million, with a yearly change of 19.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €692.11 Million | +2.35% |
| 2025 | €676.21 Million | +44.42% |
| 2024 | €468.23 Million | +23.65% |
| 2023 | €378.67 Million | +97.79% |
| 2022 | €191.45 Million | +18.02% |
| 2021 | €162.23 Million | +55.63% |
| 2020 | €104.24 Million | +3.48% |
| 2019 | €100.73 Million | +7.08% |
| 2018 | €94.07 Million | +1.03% |
| 2017 | €93.11 Million | -3.11% |
| 2016 | €96.10 Million | -9.97% |
| 2015 | €106.74 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 11th, 2026 the market cap of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $692.11 Million USD |
| MoneyControl | $692.11 Million USD |
| MarketWatch | $692.11 Million USD |
| marketcap.company | $692.11 Million USD |
| Reuters | $692.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and… Read more